Anticancer Drug Discovery

Rayman MP, Combs GF Jr, Waters DJ. Selenium and vitamin E supplementation for cancer prevention. JAMA 2009; 301(18):1876.

Turk MJ, Waters DJ, Low PS. Folate-mediated targeting of liposomes to ascites tumor cells and tumor-associated macrophages in vivo. Cancer Letters, 2004; 213:165-172.

Waters DJ, Chiang EC, Cooley DM, Morris JS. Making sense of sex and supplements: differences in the anticarcinogenic effects of selenium in men and women. Mutat Res 2004;551:91-107.

Mathias CJ, Lewis MR, Reichert DE, Laforest R, Sharp TL, Yang ZF, Waters DJ , Snyder PW, Low PS, Welch MJ, Green M. Preparation of ⁶⁶Ga- and ⁶⁸ Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nuclear Med Biol 2003; 30:725-31.

Mathias CJ, Wang S, Low PS, Waters DJ, Green MA. Receptor-mediated targeting of 67Ga-deferoxamine-folate to folate receptor positive human KB tumor xenografts. Nucl Med Biol 1999; 26:23-25.

Mathias CJ, Wang S, Waters DJ, Turek JJ, Low PS, Green MA. 111 In-DTPA-Folate as a potential folate receptor-targeted radiopharmaceutical. J Nucl Med 1998; 39:1579-85.

Wang S, Luo J, Lantrip DA, Waters DJ, Mathias CJ, Green MA, Fuchs PL, Low PS. Design and synthesis of 111In-DTPA-Folate for use as a tumor-targeted radiopharmaceutical. Bioconjugate Chemistry 1997; 7:56-62.

Mathias CJ, Lee RJ, Wang S, Waters DJ, Low PS, Green MA. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67 deferoxamine-folate. J Nucl Med 1996; 37:003-08.

Chang C-j, Ashendel CL, Geahlen RL, McLaughlin JL, Waters DJ. Oncogene signal transduction inhibitors from medicinal plants. In Vivo 1996; 10:185-190.